Trevi Therapeutics/$TRVI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Ticker
$TRVI
Sector
Primary listing
Employees
33
Headquarters
Website
TRVI Metrics
BasicAdvanced
$1.3B
-
-$0.42
0.59
-
Price and volume
Market cap
$1.3B
Beta
0.59
52-week high
$11.83
52-week low
$2.36
Average daily volume
1.6M
Financial strength
Current ratio
22.425
Quick ratio
22.153
Long term debt to equity
0.305
Total debt to equity
0.449
Interest coverage (TTM)
-25,760.50%
Profitability
EBITDA (TTM)
-51.372
Effective tax rate (TTM)
0.10%
Management effectiveness
Return on assets (TTM)
-22.83%
Return on equity (TTM)
-35.74%
Valuation
Price to book
6.75
Price to tangible book (TTM)
6.75
Price to free cash flow (TTM)
-29.359
Free cash flow yield (TTM)
-3.41%
Free cash flow per share (TTM)
-0.375
Growth
Earnings per share change (TTM)
6.99%
3-year earnings per share growth (CAGR)
-22.00%
What the Analysts think about TRVI
Analyst ratings (Buy, Hold, Sell) for Trevi Therapeutics stock.
Bulls say / Bears say
Haduvio’s Phase 2a RIVER trial achieved its primary endpoint with a statistically significant 57% placebo-adjusted reduction in 24-hour cough frequency (p < 0.0001), marking the first clinical proof of concept in both RCC and IPF chronic cough patients (PR Newswire).
Phase 2b CORAL topline data in June 2025 demonstrated consistent, clinically meaningful reductions in cough frequency across all Haduvio dose arms in IPF patients, validating the drug’s dose-response and supporting advancement to pivotal studies (Nasdaq).
A $115 million underwritten offering closed in August 2025 has extended Trevi’s cash runway into 2029, de-risking near-term financing needs and underpinning late-stage development activities (Nasdaq).
Continued operating losses underscore the path to profitability as Trevi reported a net loss of $10.4 million in Q1 2025, highlighting ongoing cash burn from R&D and G&A expenses (Investing.com).
Haduvio remains investigational with no products approved, leaving the company’s valuation entirely contingent on the success of future clinical and regulatory milestones (PR Newswire).
Equity dilution risk persists following two recent underwritten offerings—$50 million in December 2024 and $115 million in August 2025—potentially weighing on shareholder value (PR Newswire; Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
TRVI Financial Performance
Revenues and expenses
TRVI Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Trevi Therapeutics stock?
Trevi Therapeutics (TRVI) has a market cap of $1.3B as of November 08, 2025.
What is the P/E ratio for Trevi Therapeutics stock?
The price to earnings (P/E) ratio for Trevi Therapeutics (TRVI) stock is 0 as of November 08, 2025.
Does Trevi Therapeutics stock pay dividends?
No, Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next Trevi Therapeutics dividend payment date?
Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders.
What is the beta indicator for Trevi Therapeutics?
Trevi Therapeutics (TRVI) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.